Limited Survival Benefit of Short-Course Neoadjuvant Gemcitabine Plus Nab-Paclitaxel for Resectable Pancreatic Cancer: A Prospective Phase II Study With a Propensity Score-Matched Analysis.
Oct 2026· Journal of Surgical Research· Vol 328, pp.
74-84
· 0 citations· 30 references
Medicine
TL;DR
Prolonged preoperative GnP may improve outcomes, suggesting that treatment duration may be a key determinant of efficacy, and survival comparable to historical controls treated with upfront surgery is demonstrated.
Abstract
INTRODUCTION
The optimal duration and clinical benefit of neoadjuvant gemcitabine plus nab-paclitaxel (GnP) for resectable pancreatic cancer (RPC) remain uncertain.
Methods
We conducted a prospective single-arm phase II study evaluating neoadjuvant GnP in RPC. The primary end point was 2-y relapse-free survival (RFS). Secondary end points included R0 resection rate, safety, overall survival, and the impact of treatment duration on survival outcomes. Survival outcomes were compared with those of a propensity score-matched historical cohort that underwent upfront surgery.
Results
Twenty-eight patients were analyzed. The objective response rate was 17.9%, and curative resection was achieved in 85.7%. Grade ≥3 neutropenia occurred in 64.3% without febrile neutropenia, indicating manageable toxicity. The median RFS was 15.7 mo (95% confidence interval, 12.3-19.2), with a 2-y RFS rate of 29.9%, and the median overall survival was 32.9 mo (95% confidence interval, 30.0-38.8). Propensity score-matched analysis demonstrated survival comparable to historical controls treated with upfront surgery. However, patients who completed four cycles of GnP showed a trend toward longer survival than those receiving two cycles.
Conclusions
Neoadjuvant GnP provides acceptable safety and tumor control but limited survival benefit in RPC. Prolonged preoperative GnP may improve outcomes, suggesting that treatment duration may be a key determinant of efficacy.
It is suggested that GnP-based CRT showed encouraging clinical activity with manageable toxicity in patients with LAPC, and future studies are needed to validate the additional benefits of radiotherapy.
Hironori Yamada, H. Tanaka, S. Yamada et al.· International Journal of Can...· 0 citations
BACKGROUND
Neoadjuvant therapy can improve the survival outcomes of patients with borderline resectable pancreatic cancer (BRPC). However, standard neoadjuvant regimens remain lacking. This study evaluated the clinical feasibility of tislelizumab plus gemcitabine and nab-paclitaxel in the neoadjuvant setting for BRPC....
Yong-Gang He, Xue-Hui Peng, Chen-Hao Jiang et al.· Annals of Surgical Oncology· 0 citations
In treatment-naive and recurrent LA-OSCC, neoadjuvant chemoimmunotherapy followed by response-directed R0 resection and risk-adapted radiotherapy was associated with improved OS, and retrospective associations warrant confirmation in prospective randomized trials.
Qi-Wei Wang, Yan Liu, L. Zuo et al.· Annals medicus· 0 citations
BACKGROUND
Technically resectable locally advanced head and neck squamous cell carcinoma may require highly morbid surgery. We evaluated short-course neoadjuvant anlotinib plus paclitaxel-cisplatin as a signal-generating strategy.
METHODS
Twenty-one patients received two 21-day cycles in a prospective, single-arm Pha...
Ran Xu, M.-J. Huang, Zhen-Hua Jiang et al.· Head and Neck· 0 citations
Surgical resection following neoadjuvant therapy is associated with prolonged survival in borderline resectable and locally advanced pancreatic cancer (BRPC/LAPC), yet whether this reflects improved local disease control alone or identifies patients with intrinsically favorable disease biology remains uncertain....
Todd A. Aguilera, P. Parikh, J. Frakes et al.· Cancer Research· 0 citations
BACKGROUND
Despite curative resection and adjuvant capecitabine, about 50% of biliary tract cancer (BTC) patients have tumour recurrence or die within two years. Combination chemotherapy with cisplatin and gemcitabine (CisGem) is an established palliative chemotherapy regimen BTC, which has been evaluated in the adjuva...
A. Stein, J. Bridgewater, H. Klümpen et al.· Annals of Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.